Amgen reports Repatha 20% death risk reduction
Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV trial results showing Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults without previous heart attack or stroke over a median 4.6-year follow-up.










